Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio

Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.

We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.

Read the original at bloomberg.com →

More in Finance & Markets

[Closing Market] KOSPI Settles Above 5,800 on Institutional Buying

On Nov. 2, the first trading day of November and the beginning of the week, the domestic stock market briskly started weekly trading with a strong rebound, completely shaking off the shock of external…

  • KOSPI index settles at 5,859.08, up 2.24% from previous session
  • Large institutional buying drives market rally
  • KOSDAQ index rises to 734.36, up 1.38%

More from Monday 2 November →